{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:50:35Z","timestamp":1783335035916,"version":"3.54.6"},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,7,1]]},"DOI":"10.2169\/internalmedicine.4148-19","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T22:04:02Z","timestamp":1586383442000},"page":"1665-1669","source":"Crossref","is-referenced-by-count":4,"title":["Neurofibromatosis Type 1 with the Development of Pheochromocytoma and Breast Cancer"],"prefix":"10.2169","volume":"59","author":[{"given":"Yu Hee","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Inje University, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jeong","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Inje University, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hyun","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Inje University, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Pathology, College of Medicine, Inje University, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery, College of Medicine, Inje University, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Woong","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Radiology, College of Medicine, Inje University, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Inje University, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol 141: 71-74, 2005.","DOI":"10.1001\/archderm.141.1.71"},{"key":"2","unstructured":"2. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A: 327-332, 2010."},{"key":"3","unstructured":"3. Uusitalo E, Lepp\u00e4virta J, Koffert A, et al. Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol 135: 904-906, 2015."},{"key":"4","unstructured":"4. Evans DG, O'Hara C, Wilding A, et al. Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet 19: 1187-1191, 2011."},{"key":"5","unstructured":"5. Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 68: 1110-1118, 2001."},{"key":"6","unstructured":"6. Masocco M, Kodra Y, Vichi M, et al. Mortality associated with neurofibromatosis type 1: a study based on Italian death certificates (1995-2006). Orphanet J Rare Dis 6: 11, 2011."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Z\u00f6ller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in G\u00f6teborg, Sweden. Acta Derm Venereol 75: 136-140, 1995.","DOI":"10.2340\/0001555575136140"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45: 575-578, 1988.","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Evans DG, Bowers N, Burkitt-Wright E, et al. Comprehensive RNA analysis of the NF1 gene in classically affected NF1 affected individuals meeting NIH criteria has high sensitivity and mutation negative testing is reassuring in isolated cases with pigmentary features only. EBioMedicine 7: 212-220, 2016.","DOI":"10.1016\/j.ebiom.2016.04.005"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Uusitalo E, Rantanen M, Kallionp\u00e4\u00e4 RA, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol 34: 1978-1986, 2016.","DOI":"10.1200\/JCO.2015.65.3576"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Demirpence MM, Bahceci M, Dolek D, Salgur F, Gorgel A, Tutuncuoglu P. A very rare assoc\u0131at\u0131on; coex\u0131stence of breast cancer, pheochromocytoma and Neurof\u0131bromatos\u0131s. Int J Case Rep Med 2013: 2013.","DOI":"10.5171\/2013.511990"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM. von Recklinghausen's disease and pheochromocytomas. J Urol 162: 1582-1586, 1999.","DOI":"10.1016\/S0022-5347(05)68171-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Guerrero MA, Schreinemakers JM, Vriens MR, et al. Clinical spectrum of pheochromocytoma. J Am Coll Surg 209: 727-732, 2009.","DOI":"10.1016\/j.jamcollsurg.2009.09.022"},{"key":"14","unstructured":"14. Zografos GN, Vasiliadis GK, Zagouri F, et al. Pheochromocytoma associated with neurofibromatosis type 1: concepts and current trends. World J Surg Oncol 8: 14, 2010."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Walker L, Thompson D, Easton D, et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 95: 233-238, 2006.","DOI":"10.1038\/sj.bjc.6603227"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sharif S, Moran A, Huson SM, et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 44: 481-484, 2007.","DOI":"10.1136\/jmg.2007.049346"},{"key":"17","unstructured":"17. Wang X, Levin AM, Smolinski SE, Vigneau FD, Levin NK, Tainsky MA. Breast cancer and other neoplasms in women with neurofibromatosis type 1: a retrospective review of cases in the Detroit metropolitan area. Am J Med Genet A 158a: 3061-3064, 2012."},{"key":"18","unstructured":"18. Evans DGR, Kallionp\u00e4\u00e4 RA, Clementi M, et al. Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study. Genet Med 22: 398-406, 2020."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Dischinger PS, Tovar EA, Essenburg CJ, et al. NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer. NPJ Breast Cancer 4: 29, 2018.","DOI":"10.1038\/s41523-018-0080-8"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yap YS, McPherson JR, Ong CK, et al. The NF1 gene revisited - from bench to bedside. Oncotarget 5: 5873-5892, 2014.","DOI":"10.18632\/oncotarget.2194"},{"key":"21","unstructured":"21. Frayling IM, Mautner VF, van Minkelen R, et al. Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation. J Med Genet 56: 209-219, 2019."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Leong SP, Shen ZZ, Liu TJ, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg 34: 2308-2324, 2010.","DOI":"10.1007\/s00268-010-0683-1"},{"key":"23","unstructured":"23. Ginsburg O, Bray F, Coleman MP, et al. The global burden of women's cancers: a grand challenge in global health. Lancet 389: 847-860, 2017."},{"key":"24","unstructured":"24. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-E386, 2015."},{"key":"25","unstructured":"25. Maani N, Westergard S, Yang J, et al. NF1 patients receiving breast cancer screening: insights from The Ontario High Risk Breast Screening Program. Cancers (Basel) 11: 707, 2019."},{"key":"26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12885-015-1215-z","volume":"15","author":"AV Da Silva","year":"2015","unstructured":"26. Da Silva AV, Rodrigues FR, Pureza M, Lopes VG, Cunha KS. Breast cancer and neurofibromatosis type 1: a diagnostic challenge in patients with a high number of neurofibromas. BMC Cancer 15: 183, 2015.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/13\/59_4148-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T18:29:13Z","timestamp":1696012153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/13\/59_4148-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":26,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4148-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]}}}